Kadimastem (XTAE:KDST) ROCE % : -2,240.82% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Kadimastem ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kadimastem's annualized ROCE % for the quarter that ended in Dec. 2023 was -2,240.82%.

Kadimastem ROCE % Historical Data

The historical data trend for Kadimastem's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadimastem ROCE % Chart

Kadimastem Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-549.23

-249.57

-1,135.16

Kadimastem Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial														-330.98	-181.22	-341.61	-912.51	-2,240.82

Kadimastem ROCE % Calculation

Kadimastem's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.817	/	( ( (12.489 - 10.534)	+	(8.366 - 8.239) )	/ 2 )
	=	-11.817	/	( (1.955	+	0.127)	/ 2 )
	=	-11.817	/	1.041
	=	-1,135.16 %

Kadimastem's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-10.868	/	( ( (9.564 - 8.721)	+	(8.366 - 8.239) )	/ 2 )
	=	-10.868	/	( ( 0.843	+	0.127 )	/ 2 )
	=	-10.868	/	0.485
	=	-2,240.82 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Kadimastem (XTAE:KDST) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kadimastem ROCE % Related Terms

Thank you for viewing the detailed overview of Kadimastem's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kadimastem (XTAE:KDST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadimastem Ltd (XTAE:KDST) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

KMSTF:USA

Address

Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, ISR

Website

http://www.kadimastem.com

Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.

Kadimastem (XTAE:KDST) Headlines

No Headlines